Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & DohmefiledCriticalMerck Sharp & Dohme
Publication of AR119864A1publicationCriticalpatent/AR119864A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Se divulgan los compuestos de fórmula (1), o una sal farmacéuticamente aceptable de los mismos, donde A, X, R¹, y R² son como se definieron en la presente, dichos compuestos poseen propiedades para antagonizar PCSK9. También se describen las formulaciones farmacéuticas que comprenden los compuestos de fórmula (1) o sus sales, y métodos de tratamiento de enfermedades cardiovasculares y de afecciones relacionadas con la actividad de PCSK9, por ejemplo, aterosclerosis, hipercolesterolemia, enfermedad coronaria, síndrome metabólico, síndrome coronario agudo, o enfermedad cardiovascular relacionada y afecciones cardiometabólicas.Compounds of formula (1), or a pharmaceutically acceptable salt thereof, where A, X, R¹, and R² are as defined herein, are disclosed, said compounds possess properties to antagonize PCSK9. Pharmaceutical formulations comprising the compounds of formula (1) or their salts, and methods of treating cardiovascular diseases and conditions related to PCSK9 activity, for example, atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, syndrome acute coronary, or related cardiovascular disease and cardiometabolic conditions.
compounds of the formula, pharmaceutical compositions and methods for delivering a nucleic acid to an animal's liver and for preparing a compound of the formula
TRICICLIC COMPOUNDS, METHODS FOR THEIR PREPARATION, FARMA-CEUTICA COMPOSITION THAT INCLUDES THEM AND THEIR USE IN THE TREATMENT OF DISEASES MEASURED BY THE ACTIVITY OF KINASE PROTEINS
COMPOUND, COMPOSITION, USE OF COMPOUND OR COMPOSITION, AND METHOD FOR TREATMENT OR PREVENTION OF A DIABETIC COMPLICATION, DISEASE RELATED TO NEUROINFLAMMATION OR ATHEROSCLEROSIS